Search Results - "Quiñones Ribas, C."

5PSQ-103 Parental unmet needs on paediatric drugs expressed in forums by Vilimelis, I, Pérez-Ricart, A, Bosch Peligero, M, Calvo, A, Codina-Jiménez, C, Valls Sánchez, E, Suñé Negre, JM, Quiñones Ribas, C, Giménez-Juárez, JC

“…Background and ImportanceSocial Media (SM) could be a source of unmet needs of parents about drug use in paediatrics. Knowing subjective information (SI) can…”
Get full text

5PSQ-100 Utility of social media as a source of paediatric drug safety, a systematic review by Vilimelis, I, Pérez-Ricart, A, Bosch Peligero, M, Calvo, A, Valls Sánchez, E, Codina-Jiménez, C, Marin, S, Suñé Negre, JM, Quiñones Ribas, C, Giménez-Juárez, JC

“…Background and ImportancePaediatric population are predisposed to have more adverse drug reactions (ADR) and other drug related problems (DRP). Social media…”
Get full text

4CPS-136 Standard first day of life central parenteral nutrition, experience in real clinical practice by Bosch Peligero, M, Ginovart Galiana, G, Arias Martinez, A, Siles Baena, A, Ocaña Rico, M, Porta Ribera, R, Martín Val, A, Laguna Marmol, L, Terricabras Mas, E, Codina Jiménez, C, Quiñones Ribas, C

“…Background and ImportanceStandard parenteral nutrition (PN) solutions should generally be used over individualised PN solutions in the majority of paediatric…”
Get full text

4CPS-206 Impact of medication reconciliation in complex chronic patients by Rodriguez Bernuz, C, Morales Triadó, A, Vilaró Jaques, L, Martín Val, A, Fernàndez Fernàndez, RA, Vilariño Seijas, A, Cervero Corbella, S, Oliveras Simón, C, Quiñones Ribas, C

“…Background and importanceMedication reconciliation improves continuity of patient care by reducing prescribing errors.Aim and objectivesThe aim of the study…”
Get full text

5PSQ-053 Off-label use of rituximab in systemic autoimmune diseases by Vilariño Seijas, A, Morales Triadó, A, Carabias Ané, L, Cardona Peitx, G, Valls Sánchez, E, Codina Jiménez, C, Quiñones Ribas, C

“…Background and importanceA large number of patients with systemic autoimmune diseases (SAD) do not respond or relapse to firstline therapies. Current…”
Get full text

Intensidad de dosis recibida en el tratamiento quimioterápico del cáncer de mama by Quiñones Ribas, C., Pontón Sivillá, J.L., Margelí Vila, M., Cirauqui Cirauqui, B., Modamio Charles, P., Mariño Hernández, E.L., Bonafont Pujol, X.

“…Conocer las intensidades de dosis relativas (IDR) en pacientes con cáncer de mama y tratamiento quimioterápico. Determinar el número de pacientes donde la IDR…”
Get full text

Dose intensity received in breast cancer treatment with chemotherapy by Quiñones Ribas, C, Pontón Sivillá, J L, Margelí Vila, M, Cirauqui Cirauqui, B, Modamio Charles, P, Mariño Hernández, E L, Bonafont Pujol, X

“…To know relative dose intensity (RDI) in patients with breast cancer treated with chemotherapy. To determine the number of patients where RDI was < 85% of that…”
Get full text